Liu and colleagues, however, discovered that the transgene causes hyperactivation of c-myb by expressing an alternative transcript lacking the negative regulatory domain; this c-myb hyperactivation eventually led to MDS that progresses to transplantable AML and acute lymphoblastic leukemia (ALL) (Liu et al., 2017), and thus provides a promising model for future drug screenings. The gene discussed is MYB; the disease is myelodysplastic syndrome.